GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » ROA %

Exagen (Exagen) ROA % : -37.82% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Exagen ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Exagen's annualized Net Income for the quarter that ended in Dec. 2023 was $-22.29 Mil. Exagen's average Total Assets over the quarter that ended in Dec. 2023 was $58.94 Mil. Therefore, Exagen's annualized ROA % for the quarter that ended in Dec. 2023 was -37.82%.

The historical rank and industry rank for Exagen's ROA % or its related term are showing as below:

XGN' s ROA % Range Over the Past 10 Years
Min: -146.39   Med: -39.15   Max: -20.02
Current: -34.08

During the past 11 years, Exagen's highest ROA % was -20.02%. The lowest was -146.39%. And the median was -39.15%.

XGN's ROA % is ranked worse than
71.73% of 237 companies
in the Medical Diagnostics & Research industry
Industry Median: -5.81 vs XGN: -34.08

Exagen ROA % Historical Data

The historical data trend for Exagen's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen ROA % Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.54 -20.02 -26.61 -45.20 -33.09

Exagen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61.14 -37.17 -27.96 -34.63 -37.82

Competitive Comparison of Exagen's ROA %

For the Diagnostics & Research subindustry, Exagen's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exagen's ROA % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exagen's ROA % distribution charts can be found below:

* The bar in red indicates where Exagen's ROA % falls into.



Exagen ROA % Calculation

Exagen's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-23.689/( (86.221+56.944)/ 2 )
=-23.689/71.5825
=-33.09 %

Exagen's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-22.292/( (60.928+56.944)/ 2 )
=-22.292/58.936
=-37.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Exagen  (NAS:XGN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-22.292/58.936
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-22.292 / 55.06)*(55.06 / 58.936)
=Net Margin %*Asset Turnover
=-40.49 %*0.9342
=-37.82 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Exagen ROA % Related Terms

Thank you for viewing the detailed overview of Exagen's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Exagen (Exagen) Business Description

Traded in Other Exchanges
Address
1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux officer: Chief Scientific Officer C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081